Clive Ballard, MD

Clive Ballard, MD, spoke on the safety data of pimavanserin, which was presented at the 2021 AAIC meeting, held from July 26-30.

Clive Ballard, MD, professor of age related diseases at University of Exeter, commented on the potential impact that the approval of pimavanserin would have for patients if approved for dementia-related psychosis.

Clive Ballard, MD, spoke on safety data presented at this year’s AAIC meeting, as well as the impact of symptoms associated with DRP, which can be distressing for individuals and their families.

Ballard, a professor of age related diseases at University of Exeter, discussed the results from a recent trial of pimavanserin in dementia-related psychosis, and data presented at this year’s AAIC meeting.

Clive Ballard, MD, discussed up-and-coming technologies for remote risk assessment, among other data presented at this year’s AAIC meeting.

The dean at the University of Exeter Medical School discussed ongoing studies of pimavanserin and his thoughts on the FDA’s actions related to the agent.

The dean at the University of Exeter Medical School discussed the questions related to treating dementia-related psychosis and the options available.

The professor of age-related diseases and Dean of the University of Exeter Medical School spoke about the need for proper training of nursing home staff in order to improve quality of life in patients with dementia.

Efficacy was demonstrated in this patient population at the primary endpoint of 6 weeks, especially in those with more severe baseline NPI-NH-PS.